Late biocompatibility is now the next challenge for DES technology: what is the scope of the problem? Do we know the clinical impact? How can we manage this issue with existing solutions?
|
||||||||||||||
|
||||||||||||||
Late biocompatibility is now the next challenge for DES technology: what is the scope of the problem? Do we know the clinical impact? How can we manage this issue with existing solutions?
|
||||||||||||||
|
||||||||||||||
© 2010 CongrHealth.com - All rights reserved